V
Vaibhav Sahai
Researcher at University of Michigan
Publications - 118
Citations - 4722
Vaibhav Sahai is an academic researcher from University of Michigan. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 27, co-authored 81 publications receiving 2597 citations. Previous affiliations of Vaibhav Sahai include Harvard University & Northwestern University.
Papers
More filters
Journal ArticleDOI
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Vaibhav Sahai,Antoine Hollebecque,Gina M. Vaccaro,Davide Melisi,Raed Al-Rajabi,Andrew Scott Paulson,Mitesh J. Borad,David Gallinson,Adrian Murphy,Do Youn Oh,Efrat Dotan,Daniel V.T. Catenacci,Eric Van Cutsem,Tao Ji,Christine F. Lihou,Hui-Ling Zhen,Luis Féliz,Arndt Vogel +19 more
TL;DR: These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.
Journal ArticleDOI
Hepatobiliary cancers, Version 2.2021
Al B. Benson,Michael I. D’Angelica,Daniel E. Abbott,Daniel A. Anaya,Robert A. Anders,Chandrakanth Are,Melinda Bachini,Mitesh J. Borad,Daniel B. Brown,Adam M. Burgoyne,Prabhleen Chahal,Daniel T. Chang,Jordan M. Cloyd,Anne M. Covey,Evan S. Glazer,Lipika Goyal,William G. Hawkins,Renuka Iyer,Rojymon Jacob,R. Kate Kelley,Robin D. Kim,Matthew H. Levine,Manisha Palta,James O. Park,Steven S. Raman,Sanjay S. Reddy,Vaibhav Sahai,Tracey E. Schefter,Gagandeep Singh,Stacey Stein,Jean Nicolas Vauthey,Alan P. Venook,Adam C. Yopp,Nicole R. McMillian,Cindy Hochstetler,Susan Darlow +35 more
TL;DR: The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts as discussed by the authors.
Journal ArticleDOI
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
Michael J. Pishvaian,Edik M. Blais,Jonathan R. Brody,Emily Lyons,Patricia DeArbeloa,Andrew Eugene Hendifar,Sam Mikhail,Vincent Chung,Vaibhav Sahai,Davendra Sohal,Sara Bellakbira,Dzung Thach,Lola Rahib,Subha Madhavan,Lynn M. Matrisian,Emanuel F. Petricoin +15 more
TL;DR: Real-world outcomes suggest that the adoption of precision medicine can have a substantial effect on survival in patients with pancreatic cancer, and that molecularly guided treatments targeting oncogenic drivers and the DNA damage response and repair pathway warrant further prospective evaluation.
Journal ArticleDOI
Hepatobiliary Cancers, Version 1.2017: Featured Updates to the NCCN Guidelines
Al B. Benson,Michael I. D’Angelica,Daniel E. Abbott,Thomas A. Abrams,Steven R. Alberts,Daniel Anaya Saenz,Chandrakanth Are,Daniel B. Brown,Daniel T. Chang,Anne M. Covey,William G. Hawkins,Renuka Iyer,Rojymon Jacob,Andrea Karachristos,R. Kate Kelley,Robin D. Kim,Manisha Palta,James O. Park,Vaibhav Sahai,Tracey E. Schefter,Carl Schmidt,Jason K. Sicklick,Gagandeep Singh,Davendra Sohal,Stacey Stein,G. Gary Tian,Jean Nicolas Vauthey,Alan P. Venook,Andrew X. Zhu,Karin G. Hoffmann,Susan Darlow +30 more
TL;DR: The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.
Journal ArticleDOI
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Edward J. Kim,Vaibhav Sahai,Ethan V. Abel,Kent A. Griffith,Joel K. Greenson,Naoko Takebe,Gazala N. Khan,John L Blau,Ronald A. Craig,Ulysses G. Balis,Mark M. Zalupski,Diane M. Simeone +11 more
TL;DR: It is shown that GDC-0449 for 3 weeks leads to downmodulation of GLI1 and PTCH1, without significant changes in CSCs compared with baseline, which was not superior to gemcitabine alone in the treatment of metastatic pancreatic cancer.